Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Ticking off Lyme disease: OspA mRNA vaccine halts infection in mouse model

Journal Article · · Molecular Therapy Nucleic Acids
 [1];  [1];  [1];  [2];  [3]
  1. Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)
  2. Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
  3. Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
+ Show Author Affiliations
Lyme disease, a condition caused by Borrelia burgdorferi sensu lato and transmitted to humans via ticks, affects approximately 676,000 individuals annually in the United States and Western Europe.1 Currently, there is no approved Lyme vaccine available for human use. A promising study by Tahir et al., published in Molecular Therapy Nucleic Acids, investigated the efficacy of mRNA and subunit vaccines targeting Lyme disease.2 This research demonstrated complete protection from infection in a tick-fed mouse model using an outer surface protein A (OspA) mRNA vaccine. Although mRNA vaccines have shown success against viral pathogens, their clinical application against bacterial diseases has been limited.3 Thus, this study represents an important step toward developing an effective mRNA vaccine against Lyme disease.
Research Organization:
Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States); Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
Sponsoring Organization:
USDOE; USDOE National Nuclear Security Administration (NNSA)
Grant/Contract Number:
AC05-76RL01830; AC52-07NA27344
OSTI ID:
2587961
Alternate ID(s):
OSTI ID: 2585359
Report Number(s):
LLNL--JRNL-2007650; PNNL-SA--211550
Journal Information:
Molecular Therapy Nucleic Acids, Journal Name: Molecular Therapy Nucleic Acids Journal Issue: 3 Vol. 36; ISSN 2162-2531
Publisher:
Elsevier BVCopyright Statement
Country of Publication:
United States
Language:
English

References (10)

mRNA vaccine platforms to prevent bacterial infections journal June 2024
A Lyme disease mRNA vaccine targeting Borrelia burgdorferi OspA induces strong immune responses and prevents transmission in mice journal June 2025
SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses journal November 2023
Development of an mRNA-lipid nanoparticle vaccine against Lyme disease journal September 2023
Design of a broadly reactive Lyme disease vaccine journal May 2020
Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine journal August 2020
CD4+T Cells Promote Antibody Production but Not Sustained Affinity Maturation during Borrelia burgdorferi Infection journal January 2015
Comparison of Lyme Disease in the United States and Europe journal August 2021
Infection Kinetics and Tropism of Borrelia burgdorferi sensu lato in Mouse After Natural (via Ticks) or Artificial (Needle) Infection Depends on the Bacterial Strain journal July 2018
Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice. journal December 1996

Figures / Tables (1)

Figure 1(p. 2)figure Figure 1

Similar Records

A New Approach to a Lyme Disease Vaccine
Journal Article · Mon Jan 31 23:00:00 EST 2011 · Clinical Infectious Diseases · OSTI ID:1019449
Whole genome sequence of an unusual Borrelia burgdorferi sensu lato isolate
Journal Article · Mon Feb 28 23:00:00 EST 2011 · Journal of Bacteriology · OSTI ID:1025498

Related Subjects